Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
Year: 2022
Type: article
Study design: Observational Study
Source: Blood
Authors: Matthew A. Lunning, Hai-Lin Wang, Zhen-Huan Hu, Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson, Sairah Ahmed, David B. Miklos, Yi Lin, Brian T. Hill, Armin Ghobadi, Sattva S. Neelapu, Jason Westin, Harry Miao, Shilpa Shahani, Anik R. Patel, Clare Spooner, Christine Fu, Hairong Xu, Marcelo C Pasquini
Institutions: University of Nebraska at Omaha, Moffitt Cancer Center, City Of Hope National Medical Center, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Stanford University, Mayo Clinic, Cleveland Clinic, Washington University in St. Louis, Medical College of Wisconsin
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310161872